Drugs that contain Crizotinib
1. Drug name - XALKORI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8785632 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar, 2025
(2 years from now) | |
| US7230098 | PF PRISM CV | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug, 2025
(2 years from now) | |
| US7858643 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Oct, 2029
(7 years from now) | |
| US8217057 | PF PRISM CV | Polymorphs of a c-MET/HGFR inhibitor |
Nov, 2029
(7 years from now) | |
| CN103265477A | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| CN103265477B | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| CN101023064B | PF PRISM CV | As Protein Kinase Inhibitors Of Enantiomer Pure Amino Heteroaryl Compound |
Aug, 2025
(2 years from now) | |
| CN101023064A | PF PRISM CV | The Enantiomer Pure Amino Heteroaryl Compound As Protein Kinase Inhibitor |
Aug, 2025
(2 years from now) | |
| CN101326175B | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| CN101326175A | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| IN200503734P1 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| IN249316B | PF PRISM CV | An Amino-Pyridine Compound Of Formula I |
Feb, 2024
(1 year, 4 months from now) | |
| IN200700144P1 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Aug, 2025
(2 years from now) | |
| IN250050B | PF PRISM CV | An Enantiomerically Pure Aminopyridine Compound Of Formula (I) |
Aug, 2025
(2 years from now) | |
| EP1603570A2 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP2476667A2 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1603570A4 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP2476667B1 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP2476667A3 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1603570B9 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1603570B1 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1963302B1 | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1963302A2 | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1786785A2 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Oct, 2027
(5 years from now) | |
| EP1786785B1 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Oct, 2027
(5 years from now) | |
| EP1786785B9 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Oct, 2027
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7825137 | PF PRISM CV | Method of treating abnormal cell growth |
May, 2027
(4 years from now) | |
Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | CAPSULE;ORAL | Prescription |
| 250MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.